loratadine has been researched along with Pruritus in 32 studies
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.
loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.
Pruritus: An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy and side effects of gabapentin and desloratadine in patients with dialysis pruritus." | 9.16 | Uremic pruritus in hemodialysis patients: treatment with desloratidine versus gabapentin. ( Barrón, B; Lauxmann, JE; Marquez, D; Martinatto, C; Novoa, PA; Orías, M; Peixoto, AJ; Ramonda, C; Romero, CA; Vukelic, VL, 2012) |
| "Levocetirizine led to a significantly greater decrease in pruritus severity than desloratadine over the first treatment week; mean pruritus severity scores of 1." | 9.14 | Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. ( Finlay, AY; Guillet, G; Hauptmann, P; Jian, AM; Kapp, A; Maurer, M; Potter, PC, 2009) |
| "Our data show a tendency to suppressive effect of montelukast on flare and itching but not on wheal which is basic for SPT interpretation." | 9.12 | The effect of montelukast (10mg daily) and loratadine (10mg daily) on wheal, flare and itching reactions in skin prick tests. ( Górski, P; Kuna, P; Kupczyk, M; Kupryś, I, 2007) |
| "Desloratadine treatment was associated with significant improvements compared with placebo in pruritus scores and in the size of the largest wheals as early as day 1." | 9.12 | Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. ( Auquier, P; Dreyfus, I; Grob, JJ; Ortonne, JP, 2007) |
| "To compare the efficacy and tolerance of naltrexone and loratadine in uremic pruritus." | 9.11 | A comparative study on the effects of naltrexone and loratadine on uremic pruritus. ( Clèdes, J; Legroux-Crespel, E; Misery, L, 2004) |
| " Both desloratadine alone and desloratadine plus montelukast administered once daily yielded improvements with respect to the baseline assessment as regards pruritus, number of separate episodes, size and number of weals, visual analogue score and patients' quality of life and with respect to the placebo group both in the active treatment period and in the run-out period." | 9.11 | Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. ( Colanardi, MC; Ferrannini, A; Nettis, E; Paradiso, MT, 2004) |
| "To compare the clinical efficacy and safety of mizolastine with loratadine and placebo in patients with chronic idiopathic urticaria (CIU)." | 9.09 | Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. ( Dubertret, L; Murrieta Aguttes, M; Tonet, J, 1999) |
| "Desloratadine was superior to placebo in controlling pruritus and total symptoms after the first dose and maintained this superiority to the end of the study." | 9.09 | Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. ( Bronsky, E; Gauger, A; Hein, R; Miller, B; Ring, J, 2001) |
| "The aim of the study was to assess the therapeutic efficacy of loratadine on pruritus in patients with atopic dermatitis, considering the patients' sensation of itch." | 9.07 | Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study. ( Fagertun, HE; Langeland, T; Larsen, S, 1994) |
| " Desloratadine therapy significantly reduced nasal and ocular symptom severity, itching and wheals, and sleep and activity disruption (p < 0." | 8.86 | Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. ( Bachert, C; Maurer, M, 2010) |
| "Loratadine was safe and well tolerated with sedation and dry mouth similar to placebo and significantly less than hydroxyzine." | 6.67 | Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. ( Bernstein, DI; Cuss, F; Danzig, MR; Fox, RW; Garvin, PR; Grabiec, SV; Honsinger, RW; Kalivas, JT; Katz, HI; Monroe, EW, 1992) |
| "To compare the efficacy and side effects of gabapentin and desloratadine in patients with dialysis pruritus." | 5.16 | Uremic pruritus in hemodialysis patients: treatment with desloratidine versus gabapentin. ( Barrón, B; Lauxmann, JE; Marquez, D; Martinatto, C; Novoa, PA; Orías, M; Peixoto, AJ; Ramonda, C; Romero, CA; Vukelic, VL, 2012) |
| "Levocetirizine led to a significantly greater decrease in pruritus severity than desloratadine over the first treatment week; mean pruritus severity scores of 1." | 5.14 | Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. ( Finlay, AY; Guillet, G; Hauptmann, P; Jian, AM; Kapp, A; Maurer, M; Potter, PC, 2009) |
| "Our data show a tendency to suppressive effect of montelukast on flare and itching but not on wheal which is basic for SPT interpretation." | 5.12 | The effect of montelukast (10mg daily) and loratadine (10mg daily) on wheal, flare and itching reactions in skin prick tests. ( Górski, P; Kuna, P; Kupczyk, M; Kupryś, I, 2007) |
| "Desloratadine treatment was associated with significant improvements compared with placebo in pruritus scores and in the size of the largest wheals as early as day 1." | 5.12 | Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. ( Auquier, P; Dreyfus, I; Grob, JJ; Ortonne, JP, 2007) |
| "This study was conducted to assess the pharmacodynamic effects (ie, inhibition of wheal response to cutaneous histamine challenge, and subjective assessments of itching, flare, and pain) and tolerability of the fast-dissolving 20-mg ebastine tablet formulation compared with desloratadine 5-mg capsule and placebo." | 5.12 | Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): a randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adult ( Antonijoan, R; Barbanoj, MJ; Esbrí, R; Fortea, J; García-Gea, C; Pérez, J; Puntes, M; Serra, C, 2007) |
| "To compare the efficacy and tolerance of naltrexone and loratadine in uremic pruritus." | 5.11 | A comparative study on the effects of naltrexone and loratadine on uremic pruritus. ( Clèdes, J; Legroux-Crespel, E; Misery, L, 2004) |
| " Both desloratadine alone and desloratadine plus montelukast administered once daily yielded improvements with respect to the baseline assessment as regards pruritus, number of separate episodes, size and number of weals, visual analogue score and patients' quality of life and with respect to the placebo group both in the active treatment period and in the run-out period." | 5.11 | Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. ( Colanardi, MC; Ferrannini, A; Nettis, E; Paradiso, MT, 2004) |
| "Olopatadine hydrochloride is one of the second-generation nonsedating antihistamines that are used for treating allergic disorders such as urticaria, rhinitis, and atopic dermatitis." | 5.10 | Rapid effects of olopatadine hydrochloride on the histamine-induced skin responses. ( Furue, M; Koga, T; Morita, K; Moroi, Y; Urabe, K, 2002) |
| "This comparative study in mosquito-bite-sensitive adults shows that cetirizine and ebastine decrease significantly whealing and accompanying pruritus, and that cetirizine seems to be the most effective against pruritus." | 5.10 | Comparison of cetirizine, ebastine and loratadine in the treatment of immediate mosquito-bite allergy. ( Burri, P; Karppinen, A; Kautiainen, H; Petman, L; Reunala, T, 2002) |
| "To compare the clinical efficacy and safety of mizolastine with loratadine and placebo in patients with chronic idiopathic urticaria (CIU)." | 5.09 | Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. ( Dubertret, L; Murrieta Aguttes, M; Tonet, J, 1999) |
| "Desloratadine was superior to placebo in controlling pruritus and total symptoms after the first dose and maintained this superiority to the end of the study." | 5.09 | Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. ( Bronsky, E; Gauger, A; Hein, R; Miller, B; Ring, J, 2001) |
| "The aim of the study was to assess the therapeutic efficacy of loratadine on pruritus in patients with atopic dermatitis, considering the patients' sensation of itch." | 5.07 | Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study. ( Fagertun, HE; Langeland, T; Larsen, S, 1994) |
| " However, fexofenadine probably leads to a small improvement in patient-assessed pruritus, with probably no significant difference in the amount of treatment used to prevent eczema flares." | 5.01 | Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema. ( Apfelbacher, CJ; Böhmer, MM; Carter, B; Jupiter, A; Matterne, U; Weisshaar, E, 2019) |
| " Desloratadine therapy significantly reduced nasal and ocular symptom severity, itching and wheals, and sleep and activity disruption (p < 0." | 4.86 | Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. ( Bachert, C; Maurer, M, 2010) |
| "Montelukast is a leukotriene receptor antagonist recently approved for the treatment of seasonal allergic rhinitis (SAR)." | 2.71 | Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. ( Arastu, R; Baidoo, CA; Faris, MA; Howland, WC; Klein, KC; Philpot, EE; Ratner, PH; Rickard, KA, 2003) |
| "Levocetirizine was used as a comparator." | 2.71 | Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. ( Boutsiouki, P; Church, MK; Clough, GF; Denham, KJ, 2003) |
| "Escin has satisfactory effect in treating pruritus caused by blood stasis and wind-dryness." | 2.71 | [Clinical effect of escin on patients with cutaneous pruritus caused by blood stasis and wind-dryness]. ( Fan, B; Gu, DQ; Li, B; Li, FL; Xu, R; Xu, WB; Zhang, M; Zhou, M; Zhou, R, 2004) |
| "Loratadine was safe and well tolerated with sedation and dry mouth similar to placebo and significantly less than hydroxyzine." | 2.67 | Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. ( Bernstein, DI; Cuss, F; Danzig, MR; Fox, RW; Garvin, PR; Grabiec, SV; Honsinger, RW; Kalivas, JT; Katz, HI; Monroe, EW, 1992) |
| "Itching is one of the major clinical symptoms in atopic dermatitis (AD) and complicates the management of this pathological condition." | 1.33 | Spontaneous scratching behaviour in DS-Nh mice as a possible model for pruritus in atopic dermatitis. ( Arimura, A; Asakawa, M; Deguchi, M; Hikita, I; Hirasawa, T; Horikawa, T; Matsutani, T; Oku, H; Yoshioka, T, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (21.88) | 18.2507 |
| 2000's | 16 (50.00) | 29.6817 |
| 2010's | 8 (25.00) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Gong, Y | 1 |
| Zhang, Y | 1 |
| Zhou, S | 1 |
| Chen, D | 1 |
| Zhong, S | 1 |
| Qu, J | 1 |
| Liang, X | 1 |
| Matterne, U | 1 |
| Böhmer, MM | 1 |
| Weisshaar, E | 1 |
| Jupiter, A | 1 |
| Carter, B | 1 |
| Apfelbacher, CJ | 1 |
| Meijer, JM | 1 |
| van Dalen, T | 1 |
| van der Wal, B | 1 |
| Potter, PC | 1 |
| Kapp, A | 1 |
| Maurer, M | 2 |
| Guillet, G | 1 |
| Jian, AM | 1 |
| Hauptmann, P | 1 |
| Finlay, AY | 1 |
| Grubbe, RE | 1 |
| Lumry, WR | 1 |
| Anolik, R | 1 |
| Bachert, C | 1 |
| Hornby, SA | 1 |
| Schlosburg, JE | 1 |
| O'Neal, ST | 1 |
| Conrad, DH | 1 |
| Lichtman, AH | 1 |
| Mulliez, P | 1 |
| Mbassi Fouda, FL | 1 |
| Roy Saint-Georges, F | 1 |
| Paniz-Mondolfi, AE | 1 |
| Pérez-Alvarez, AM | 1 |
| Lundberg, U | 1 |
| Fornés, L | 1 |
| Reyes-Jaimes, O | 1 |
| Hernández-Pérez, M | 1 |
| Hossler, E | 1 |
| Marquez, D | 1 |
| Ramonda, C | 1 |
| Lauxmann, JE | 1 |
| Romero, CA | 1 |
| Vukelic, VL | 1 |
| Martinatto, C | 1 |
| Barrón, B | 1 |
| Novoa, PA | 1 |
| Peixoto, AJ | 1 |
| Orías, M | 1 |
| Morita, K | 1 |
| Koga, T | 1 |
| Moroi, Y | 1 |
| Urabe, K | 1 |
| Furue, M | 1 |
| Ratner, PH | 1 |
| Howland, WC | 1 |
| Arastu, R | 1 |
| Philpot, EE | 1 |
| Klein, KC | 1 |
| Baidoo, CA | 1 |
| Faris, MA | 1 |
| Rickard, KA | 1 |
| Denham, KJ | 1 |
| Boutsiouki, P | 1 |
| Clough, GF | 1 |
| Church, MK | 1 |
| Legroux-Crespel, E | 1 |
| Clèdes, J | 1 |
| Misery, L | 1 |
| Nucera, E | 1 |
| Schiavino, D | 1 |
| Pollastrini, E | 1 |
| Manna, R | 1 |
| Di Lillo, M | 1 |
| De Lillo, M | 1 |
| Buonomo, A | 1 |
| Roncallo, C | 1 |
| Patriarca, G | 1 |
| Nettis, E | 1 |
| Colanardi, MC | 1 |
| Paradiso, MT | 1 |
| Ferrannini, A | 1 |
| Li, FL | 1 |
| Xu, R | 1 |
| Zhou, R | 1 |
| Fan, B | 1 |
| Zhou, M | 1 |
| Xu, WB | 1 |
| Gu, DQ | 1 |
| Zhang, M | 1 |
| Li, B | 1 |
| Kupczyk, M | 1 |
| Kupryś, I | 1 |
| Górski, P | 1 |
| Kuna, P | 1 |
| Yoshioka, T | 1 |
| Hikita, I | 1 |
| Asakawa, M | 1 |
| Hirasawa, T | 1 |
| Deguchi, M | 1 |
| Matsutani, T | 1 |
| Oku, H | 1 |
| Horikawa, T | 1 |
| Arimura, A | 1 |
| Ortonne, JP | 1 |
| Grob, JJ | 1 |
| Auquier, P | 1 |
| Dreyfus, I | 1 |
| Antonijoan, R | 1 |
| García-Gea, C | 1 |
| Puntes, M | 1 |
| Pérez, J | 1 |
| Esbrí, R | 1 |
| Serra, C | 1 |
| Fortea, J | 1 |
| Barbanoj, MJ | 1 |
| Langeland, T | 1 |
| Fagertun, HE | 1 |
| Larsen, S | 1 |
| Day, JH | 1 |
| Briscoe, MP | 1 |
| Clark, RH | 1 |
| Ellis, AK | 1 |
| Gervais, P | 1 |
| Dubertret, L | 1 |
| Murrieta Aguttes, M | 1 |
| Tonet, J | 1 |
| Ring, J | 1 |
| Hein, R | 1 |
| Gauger, A | 1 |
| Bronsky, E | 1 |
| Miller, B | 1 |
| Karppinen, A | 1 |
| Kautiainen, H | 1 |
| Petman, L | 1 |
| Burri, P | 1 |
| Reunala, T | 1 |
| Monroe, EW | 1 |
| Bernstein, DI | 1 |
| Fox, RW | 1 |
| Grabiec, SV | 1 |
| Honsinger, RW | 1 |
| Kalivas, JT | 1 |
| Katz, HI | 1 |
| Cuss, F | 1 |
| Danzig, MR | 1 |
| Garvin, PR | 1 |
| Abu Shareeah, AM | 1 |
| Frølund, L | 1 |
| Paul, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial[NCT02646020] | Phase 2 | 138 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis[NCT00119015] | Phase 4 | 102 participants (Actual) | Interventional | 2005-07-31 | Terminated (stopped due to Difficulty in recruitment) | ||
| Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age[NCT04957927] | Phase 4 | 60 participants (Anticipated) | Interventional | 2020-12-12 | Recruiting | ||
| Nasal Ocular Reflexes Contribute to Eye Symptoms in Patients With Allergic Rhinitis[NCT00117832] | 20 participants | Interventional | 2005-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Patients recorded the severity of other symptoms, including itchy nose/eyes and post-nasal drip, twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The other symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.24 |
| Fluticasone Propionate + Placebo | -0.14 |
"Patients recorded the severity of runny nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The runny nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.52 |
| Fluticasone Propionate + Placebo | -0.29 |
"Patients recorded the severity of sneezing twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The sneezing symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.22 |
| Fluticasone Propionate + Placebo | -0.25 |
"Patients recorded the severity of stuffy nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The stuffy nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.41 |
| Fluticasone Propionate + Placebo | -0.47 |
"Patients recorded the severity of sneezing, runny nose, stuffy nose, and other symptoms (itchy nose/eyes and post-nasal drip) twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The TNSS was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 24.~The baseline TNSS used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -1.66 |
| Fluticasone Propionate + Placebo | -2.21 |
2 reviews available for loratadine and Pruritus
| Article | Year |
|---|---|
Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema.
Topics: Administration, Oral; Administration, Topical; Adult; Cetirizine; Chemotherapy, Adjuvant; Child; Ecz | 2019 |
Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.
Topics: Activities of Daily Living; Adult; Anti-Allergic Agents; Chronic Disease; Female; Germany; Histamine | 2010 |
21 trials available for loratadine and Pruritus
| Article | Year |
|---|---|
Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients.
Topics: Cetirizine; Chronic Disease; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Hu | 2009 |
Efficacy and safety of desloratadine/pseudoephedrine combination vs its components in seasonal allergic rhinitis.
Topics: Adolescent; Adult; Aged; Bronchodilator Agents; Child; Double-Blind Method; Drug Synergism; Drug The | 2009 |
Uremic pruritus in hemodialysis patients: treatment with desloratidine versus gabapentin.
Topics: Amines; Cross-Over Studies; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Histam | 2012 |
Rapid effects of olopatadine hydrochloride on the histamine-induced skin responses.
Topics: Administration, Oral; Adult; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; | 2002 |
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age | 2003 |
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age | 2003 |
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age | 2003 |
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age | 2003 |
Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin.
Topics: Adult; Anti-Allergic Agents; Cetirizine; Cross-Over Studies; Double-Blind Method; Erythema; Histamin | 2003 |
A comparative study on the effects of naltrexone and loratadine on uremic pruritus.
Topics: Antipruritics; Drug Administration Schedule; Female; Humans; Loratadine; Male; Middle Aged; Naltrexo | 2004 |
Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study.
Topics: Acetates; Administration, Oral; Adolescent; Adult; Aged; Chronic Disease; Cyclopropanes; Double-Blin | 2004 |
[Clinical effect of escin on patients with cutaneous pruritus caused by blood stasis and wind-dryness].
Topics: Adult; Aged; Aged, 80 and over; Escin; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Lorat | 2004 |
The effect of montelukast (10mg daily) and loratadine (10mg daily) on wheal, flare and itching reactions in skin prick tests.
Topics: Acetates; Allergens; Antipruritics; Capsules; Codeine; Cross-Over Studies; Cyclopropanes; Double-Bli | 2007 |
Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Histamine H1 | 2007 |
Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): a randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adult
Topics: Adolescent; Adult; Butyrophenones; Cross-Over Studies; Double-Blind Method; Female; Histamine; Hista | 2007 |
Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study.
Topics: Adult; Circadian Rhythm; Dermatitis, Atopic; Double-Blind Method; Female; Humans; Loratadine; Male; | 1994 |
Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis.
Topics: Adolescent; Adult; Anti-Allergic Agents; Astemizole; Cetirizine; Double-Blind Method; Environmental | 1997 |
Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study.
Topics: Adult; Analysis of Variance; Appendicitis; Benzimidazoles; Chronic Disease; Double-Blind Method; Ele | 1999 |
Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Cholinergic Antagonists; Chronic Disease; Dizziness; Double-Blind Method; D | 2001 |
Comparison of cetirizine, ebastine and loratadine in the treatment of immediate mosquito-bite allergy.
Topics: Adult; Animals; Butyrophenones; Cetirizine; Conscious Sedation; Cross-Over Studies; Culicidae; Doubl | 2002 |
Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Chronic Disease; Double-Blind Method; Humans; Hydroxyzine; Loratadine; Midd | 1992 |
Comparative efficacy of loratadine and terfenadine in the treatment of chronic idiopathic urticaria.
Topics: Adult; Chronic Disease; Cyproheptadine; Female; Histamine Antagonists; Humans; Loratadine; Male; Pru | 1992 |
Efficacy of an oral antihistamine, loratadine, as compared with a nasal steroid spray, beclomethasone dipropionate, in seasonal allergic rhinitis.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Beclomethasone; Cyproheptadine; Doubl | 1991 |
[Treatment of pruritic skin diseases with loratadine. Results of an open multicenter study].
Topics: Adolescent; Adult; Aged; Cyproheptadine; Drug Evaluation; Female; Histamine Antagonists; Humans; Lor | 1991 |
9 other studies available for loratadine and Pruritus
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Analysis of the clinical effect of pregabalin capsule combined with loratadine dispersible tablets in the treatment of uremic skin pruritus.
Topics: Humans; Loratadine; Pregabalin; Pruritus; Tablets | 2023 |
A Patient with Jaundice and Pruritus, Not the Usual Suspect?
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Glucocorticoids; Glutamyl Aminopeptidase; Hepatit | 2019 |
A common but interesting case history.
Topics: Adult; Antipruritics; Exercise; Humans; Loratadine; Male; Military Personnel; Naval Medicine; Prurit | 2009 |
CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Fem | 2011 |
[Cutaneous reaction after pyrazinamide initiation].
Topics: Adult; Antitubercular Agents; Drug Combinations; Drug Eruptions; Drug Therapy, Combination; Dysgeusi | 2011 |
Cutaneous lepidopterism: dermatitis from contact with moths of Hylesia metabus (Cramer 1775) (Lepidoptera: Saturniidae), the causative agent of caripito itch.
Topics: Adolescent; Adult; Anesthetics, Local; Animals; Antipruritics; Chlorpheniramine; Dermatitis, Contact | 2011 |
Tolerance induction to rofecoxib in a patient with Bartter's syndrome.
Topics: Adult; Anti-Allergic Agents; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Bartter | 2004 |
Spontaneous scratching behaviour in DS-Nh mice as a possible model for pruritus in atopic dermatitis.
Topics: Animals; Antipruritics; Cells, Cultured; Dermatitis, Atopic; Disease Models, Animal; Histamine; Hist | 2006 |